Abstract
Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p
| Original language | English |
|---|---|
| Pages (from-to) | 520-532 |
| Number of pages | 13 |
| Journal | Multiple Sclerosis Journal |
| Volume | 22 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2016 |
Fingerprint
Keywords
- disease-modifying therapy
- fingolimod
- medication persistence
- MSBase
- Multiple sclerosis
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. / Warrender-Sparkes, Matthew; Spelman, Tim; Izquierdo, Guillermo; Trojano, Maria; Lugaresi, Alessandra; Grand'Maison, François; Havrdova, Eva; Horakova, Dana; Boz, Cavit; Oreja-Guevara, Celia; Alroughani, Raed; Iuliano, Gerardo; Duquette, Pierre; Girard, Marc; Terzi, Murat; Hupperts, Raymond; Grammond, Pierre; Petersen, Thor; Fernandez-Bolaños, Ricardo; Fiol, Marcela; Pucci, Eugenio; Lechner-Scott, Jeannette; Verheul, Freek; Cristiano, Edgardo; Van Pesch, Vincent; Petkovska-Boskova, Tatjana; Moore, Fraser; Kister, Ilya; Bergamaschi, Roberto; Saladino, Maria Laura; Slee, Mark; Barnett, Michael; Amato, Maria Pia; Shaw, Cameron; Shuey, Neil; Young, Carolyn; Gray, Orla; Kappos, Ludwig; Butzkueven, Helmut; Kalincik, Tomas; Jokubaitis, Vilija.
In: Multiple Sclerosis Journal, Vol. 22, No. 4, 01.04.2016, p. 520-532.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
AU - Warrender-Sparkes, Matthew
AU - Spelman, Tim
AU - Izquierdo, Guillermo
AU - Trojano, Maria
AU - Lugaresi, Alessandra
AU - Grand'Maison, François
AU - Havrdova, Eva
AU - Horakova, Dana
AU - Boz, Cavit
AU - Oreja-Guevara, Celia
AU - Alroughani, Raed
AU - Iuliano, Gerardo
AU - Duquette, Pierre
AU - Girard, Marc
AU - Terzi, Murat
AU - Hupperts, Raymond
AU - Grammond, Pierre
AU - Petersen, Thor
AU - Fernandez-Bolaños, Ricardo
AU - Fiol, Marcela
AU - Pucci, Eugenio
AU - Lechner-Scott, Jeannette
AU - Verheul, Freek
AU - Cristiano, Edgardo
AU - Van Pesch, Vincent
AU - Petkovska-Boskova, Tatjana
AU - Moore, Fraser
AU - Kister, Ilya
AU - Bergamaschi, Roberto
AU - Saladino, Maria Laura
AU - Slee, Mark
AU - Barnett, Michael
AU - Amato, Maria Pia
AU - Shaw, Cameron
AU - Shuey, Neil
AU - Young, Carolyn
AU - Gray, Orla
AU - Kappos, Ludwig
AU - Butzkueven, Helmut
AU - Kalincik, Tomas
AU - Jokubaitis, Vilija
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p
AB - Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p
KW - disease-modifying therapy
KW - fingolimod
KW - medication persistence
KW - MSBase
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=84962517754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962517754&partnerID=8YFLogxK
U2 - 10.1177/1352458515594041
DO - 10.1177/1352458515594041
M3 - Article
AN - SCOPUS:84962517754
VL - 22
SP - 520
EP - 532
JO - Multiple Sclerosis
JF - Multiple Sclerosis
SN - 1352-4585
IS - 4
ER -